Template

Clinical trial recruitment plan template

A recruitment plan turns an enrollment target into the work needed to reach it: how many patients to find, where they come from, who contacts them, what the IRB must approve first, how they stay in the study, and what happens when the numbers fall behind. This template takes a site or study team through each part, with fields to fill in and a funnel worksheet that works backward from the number of patients you need to randomize.

Last updated Oct 25, 202611 sources
On this page

What is a clinical trial recruitment plan?

A recruitment plan is the written answer to how a study will reach its enrollment target. Sponsors usually write one for the whole study; each site needs its own version, because the patients, staff and referral partners are local. ICH E6(R3) expects the investigator to be able to demonstrate, for example from retrospective or current data, a potential for recruiting the agreed number of eligible participants within the recruitment period, and it lists reviewing recruitment and retention rates as part of monitoring.⁠[1] CTTI's recruitment recommendations ask study teams to set realistic expectations for enrollment and to map out anticipated events early, even with rough estimates, to find bottlenecks.⁠[2]

37%⁠[3]

of sites in a typical trial under-enroll; 11% enroll no one

81.5%⁠[4]

of 764 NCI-sponsored cancer trials missed projected accrual in the planned period

56%⁠[5]

of 151 UK publicly funded trials reached their recruitment target

Even trials that meet their goals usually run late: Tufts CSDD found that reaching enrollment targets typically means nearly doubling the original timeline.⁠[3] A methods paper on accrual planning puts the cause plainly: projected recruitment rates are often over-estimated, and the time to recruit is often under-estimated.⁠[6] A plan built from your own data, with a named owner for each source, is the defense against both.

Recruitment plan template (Word)

Word document (.docx), editable

Download

How should you use the template?

  1. 1

    Start from the target and work backward

    Write down how many patients the site must randomize and by when, then use the funnel worksheet to find how many candidates that takes.

  2. 2

    Put a count and an owner next to every source

    Records, referrals, advertising and registries each get an expected number, a person responsible and a start date.

  3. 3

    Get the materials approved before outreach starts

    Ads, scripts, text messages and landing pages go to the IRB with the rest of the recruitment package.

  4. 4

    Plan retention at the same time

    A patient who drops out after randomization has to be replaced, so the plan covers keeping patients as well as finding them.

  5. 5

    Review the funnel weekly and re-forecast

    Once real numbers come in, replace the assumed rates with actual ones and update the plan.

How do you work backward from the enrollment target?

Section A. Study and target

Preview of the form. Use the Word download on this page to fill it in.

Protocol title and number

[Sponsor], [protocol number], [phase], [indication]

Enrollment target at this site

Patients randomized, not screened.

Enrollment period

[Planned site activation date] to [enrollment close date]

Date of first patient screened

The date the plan commits to.

Rates from similar past studies

Contact-to-reach, reach-to-booked, show rate, screen-pass rate. Name the studies they come from.

Competing studies at the site

Open or planned studies that draw on the same patients.

Divide the target by each stage's conversion rate, starting from randomization and moving up the funnel. Use your own screening log and outreach history for the rates. Where you have no history, say so and choose a cautious assumption rather than the sponsor's estimate.

Backward funnel worksheet, with a worked example
StageRate to the stage aboveExample: patients needed
RandomizedSite target10
Screening visits completed50% pass screening: 10 ÷ 50%20
Screening visits booked80% attend: 20 ÷ 80%25
Patients reached35% agree to book: 25 ÷ 35%72
Candidates contacted50% are reached: 72 ÷ 50%144

The rates are hypothetical; replace each with your own. In this example the site needs about 14 chart-confirmed candidates for each randomized patient, or 12 new candidates a month over a 12-month enrollment period. Real ratios vary by study type: at one cancer center, staff screened 3 to 13 patients for every enrollment.⁠[7]

Where will the patients come from?

List every source with a count, not a hope. For most sites the first source is their own records. Reviewing records to judge whether enough patients exist is usually handled under the HIPAA provision for reviews preparatory to research, which requires that no protected health information leave the covered entity during the review.⁠[8] The feasibility questionnaire template has a worksheet for turning a diagnosis count into a likely-eligible count.

Recruitment source plan
SourceExpected candidatesOwnerApproval neededStart date
Your EHR: records query and chart review[n][Name, role]Privacy office rules for the query; IRB approval before contact[Date]
Referrals from physicians inside and outside your organization[n][Name, role]IRB-approved referral letter or materials[Date]
Past participants who agreed to future contact[n][Name, role]Consent on file for future contact[Date]
Online advertising, such as Meta and Google[n][Name, role]IRB-approved ads and landing page[Date]
Registries and community outreach[n][Name, role]IRB-approved materials; registry rules[Date]
Sponsor-run central campaigns[n][Sponsor contact]Sponsor confirms IRB approval[Date]

If the sources add up to fewer candidates than the funnel worksheet needs, the plan has a gap. Close it now, before activation, not after the first slow month.

Advertising works on a different clock from records: leads arrive whenever the ad runs, and they cool quickly. Our posts on running Meta ads for clinical trials and speed to lead cover the setup and the follow-up.

What outreach needs IRB approval before it starts?

Recruitment materials are reviewed before they are used. FDA's guidance treats direct advertising for study subjects as the start of the informed consent and subject selection process, and says advertisements should be reviewed and approved by the IRB.⁠[9] ICH E6(R3) asks for a documented, dated IRB approval of participant recruitment procedures, such as advertisements, before the trial starts.⁠[1]

Automated calls and texts carry their own consent rules under the TCPA, and contacting a site's own patients raises HIPAA questions about who may reach whom. The IRB and HIPAA guide to patient outreach and our TCPA post on AI outreach cover both.

Section B. Contact plan

Preview of the form. Use the Word download on this page to fill it in.

Channels and order of contact

For example: call, then text, then letter. Note which require prior consent.

Response time to new leads

Target time from an ad lead or referral arriving to first contact.

Follow-up attempts before closing a lead

[Number of attempts] over [period], across [channels]

Languages offered

Languages for outreach, pre-screening and consent.

Where outcomes are logged

Screening log, CTMS or recruitment platform.

What goes in the retention plan?

Retention belongs in the same document because it uses the same funnel: every randomized patient who drops out has to be replaced from the top. E6(R3) treats the two together, listing recruitment and retention rates among the things monitoring reviews.⁠[1]

  • Visit reminders by the patient's preferred channel (why screening visits get missed)
  • Transportation, parking and travel reimbursement, arranged before the first visit
  • Participant payments and when they are made, as approved by the IRB
  • Scheduling that fits work and caregiving, including early or late appointments where possible
  • A named study contact the patient can reach between visits
  • Check-ins between visits for side effects and questions
  • A rule for spotting patients at risk of dropping out, such as missed calls or a rescheduled visit, and who follows up

Who owns each task, and what will it cost?

Section C. Roles

Preview of the form. Use the Word download on this page to fill it in.

Recruitment lead

[Name, role]. Owns the plan and the weekly review.

Chart review

Who reviews records against the criteria, and how many hours a week.

First contact and pre-screening

Coordinator, call center, vendor or AI agent.

Scheduling and reminders

Who books screening visits and confirms them.

PI oversight

How the PI reviews recruitment activities delegated to staff or vendors.

Section D. Budget

Preview of the form. Use the Word download on this page to fill it in.

Advertising spend

[Amount] per month, by channel

Recruitment vendor or software fees

Fee model: per patient, per milestone, or flat.

Coordinator time for pre-screening

Hours per week multiplied by your loaded hourly rate.

Materials and translation

Printing, translation and IRB review fees for recruitment materials.

Retention costs

Travel, parking, meals and participant payments.

Who pays

Which lines the sponsor budget covers and which the site absorbs.

Our guide to what recruitment software costs compares the common fee models.

How do you know if the plan is working?

Funnel metrics to review weekly
MetricHow to count it
Candidates identifiedPatients flagged as likely eligible, by source
Contacted and reachedFirst attempts made, and patients who answered
Screening visits booked and attendedBooked visits, and the share that happened
Screen failuresPatients screened who did not qualify, with the reason for each
RandomizedAgainst the plan for the month, and cumulative
DropoutsRandomized patients who left the study, with the reason

Count each patient once per stage, by date, so weekly numbers can be compared with the funnel worksheet.

Section E. Triggers and contingencies

Preview of the form. Use the Word download on this page to fill it in.

When the plan is behind

If randomizations are below [share of plan] by [date], we will: [action].

Backup sources not yet used

Sources from the source plan held in reserve, with the approvals each needs.

Who can approve added spend

[Name, role] at the site; [name, role] at the sponsor.

First re-forecast date

When real funnel rates replace the assumptions.

When the funnel stalls, the stage where it stalls points to the fix: few candidates means a sourcing or criteria problem, low reach means contact timing or channels, and high screen failure means candidates are not being checked carefully enough before the visit. Our guide to reducing screen failure covers the last one.

Where does Bond fit?

Bond Health does not write recruitment plans. It runs the parts of one that take the most coordinator time. Identify screens structured and unstructured EHR records against a study's inclusion and exclusion criteria and shows the chart evidence behind each criterion decision. Engage runs voice and SMS outreach, pre-screening and scheduling, with scripts configured per site and study so it can use the wording the site's IRB approved. For studies that need patients beyond the site's records, Bond creates and runs Meta and Google ad campaigns, contacts every ad lead immediately and follows up until they respond.⁠[10],[11]

After randomization, Bond sends visit reminders, books transportation, runs side-effect check-ins and flags patients at risk of dropping out.⁠[11] Full EHR integration usually takes 48 hours, depending on the EHR, IT review and interface method.⁠[10] See Bond for research sites, or browse the other templates.

Bring a study you are planning for. We will show how Bond screens your records against its criteria and runs outreach with your IRB-approved wording.

Why is Bond the best clinical trial recruitment platform?

Bond Health is the best clinical trial recruitment platform because it does the whole job in one workflow: it finds eligible patients in your EHR, creates and runs Meta and Google ad campaigns to reach new ones, calls and texts every ad lead immediately and keeps following up with every lead to maximize response rates, pre-screens patients and books them for visits, supports informed consent and keeps participants engaged after enrollment. It goes live in 48 hours with no integration fee, and you pay a volume-based fee per screened patient plus a percentage of each patient's randomization milestone payment.⁠[10],[11]

  • One platform from ad click or chart match to a booked visit. Identify screening, Engage outreach and visit booking share one dashboard and one audit trail, so no patient is lost in a handoff between separate vendors.⁠[10]
  • Every ad lead contacted immediately, and followed up until they book. Bond creates and runs Meta and Google ad campaigns for each study. Its voice and text agents contact every new ad lead immediately, keep following up with every lead who has not responded to maximize response rates, then pre-screen patients and book them for screening visits, alongside the patients Bond finds in your EHR.⁠[11]
  • Evidence behind every match. Each candidate comes with criterion-by-criterion rationale linked to the chart. Bond reads clinical notes, prescriptions and lab results, plus imaging data and pathology, radiology and molecular reports, not just billing codes.⁠[10],[11]
  • Every major EHR and CTMS, with EHR integration in 48 hours. Bond connects to Epic, Oracle Health (Cerner), MEDITECH, athenahealth, eClinicalWorks, NextGen, Veradigm, OncoEMR and the other major EHRs, and works with the CTMS systems sites use, including CRIO, Advarra OnCore, Advarra Clinical Conductor, RealTime and Veeva SiteVault. Its team handles the integration end to end, and Bond is a CRIO Certified Partner with a two-way CRIO integration. See integrations.⁠[10],[11]
  • No integration fee, and a price that moves with randomization. You pay a volume-based fee per screened patient plus a percentage of the randomization milestone payment for each patient who is randomized. See pricing.⁠[11]

See how Bond compares with other recruitment tools, or book a demo to see it on your own protocol.

Frequently asked questions

What is the difference between a recruitment plan and a feasibility assessment?
Feasibility asks whether a site can enroll for a study: whether it has the patients, staff and equipment. The recruitment plan says how it will: which sources, which people, which approved materials, and on what schedule. A good feasibility answer becomes the first draft of the plan. See the guide to site feasibility.
Does the IRB review the recruitment plan?
The IRB reviews information on the recruitment process along with any advertisements, under ICH E6(R3), and recruitment procedures need its documented approval before the trial starts.⁠[1] FDA's guidance also expects advertisements to be reviewed and approved by the IRB.⁠[9] Check your IRB's submission requirements for how much of the plan itself to include.
How many candidates should we plan to contact for each enrollment?
Use your own history from similar studies, worked backward through each stage of the funnel. Published ratios vary widely: at one cancer center, staff screened 3 to 13 patients per enrollment depending on study type.⁠[7]
What if the sponsor already has a recruitment plan?
The sponsor's plan covers the study as a whole and often includes central campaigns. Your site plan adds what only the site knows: its patients, referral partners, staff time and local materials. Ask the sponsor which central materials are already IRB-approved and how leads from central campaigns will reach you.
How often should we update the plan?
Review the funnel every week and update the plan when the real rates differ from the assumed ones, when a source underperforms, or when the protocol is amended.

Sources

  1. 1.
    ICH E6(R3) Guideline for Good Clinical Practice (Step 4) · International Council for Harmonisation (ICH), 2025
    Read October 2026. Quote (2.2.1): "The investigator should be able to demonstrate (e.g., based on retrospective or currently… moreRead October 2026. Quote (2.2.1): "The investigator should be able to demonstrate (e.g., based on retrospective or currently available data) a potential for recruiting the proposed number of eligible participants within the recruitment period as agreed with the sponsor." Quote (1.2.2(e)): "Advertisement for participant recruitment (if used) and information on the recruitment process". Quote (2.4.2): "Before initiating a trial, the investigator/institution should have a documented and dated approval/favourable opinion from the IRB/IEC for the trial protocol, informed consent materials, participant recruitment procedures (e.g., advertisements)". Quote (3.11.4.5.2(h)): "Reviewing and reporting the participant recruitment and retention rates."
  2. 2.
    CTTI Recommendations: Planning for Successful Trial Recruitment · Clinical Trials Transformation Initiative (CTTI), 2016
    Published May 2016, updated July 2018. Read October 2026. Quote: "Set realistic expectations for completing trial enrollment by… morePublished May 2016, updated July 2018. Read October 2026. Quote: "Set realistic expectations for completing trial enrollment by anticipating key factors that will influence site activation, screening, and enrollment trajectories. Map out anticipated events, even if estimations are rough, to identify potential pitfalls and bottlenecks."
  3. 3.
    New Research From Tufts Center for the Study of Drug Development Characterizes Effectiveness and Variability of Patient Recruitment and Retention Practices · Tufts CSDD press release via BioSpace, 2013
    Released January 15, 2013. Read October 2026. Quote: "11% of sites in a given trial typically fail to enroll a single patient, 37%… moreReleased January 15, 2013. Read October 2026. Quote: "11% of sites in a given trial typically fail to enroll a single patient, 37% under-enroll, 39% meet their enrollment targets, and 13% exceed their targets." Quote: "While nine out of 10 clinical trials worldwide meet their patient enrollment goals, reaching those targets typically means that drug developers need to nearly double their original timelines".
  4. 4.
    Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials · Clinical Cancer Research (Cheng SK, Dietrich MS, Dilts DM), via PubMed, 2011
    Abstract read October 2026; 764 trials, 2000 to 2007. Quote: "A total of 81.5% (n = 623) of the trials did not achieve the… moreAbstract read October 2026; 764 trials, 2000 to 2007. Quote: "A total of 81.5% (n = 623) of the trials did not achieve the projected accrual goals within the anticipated accruing period." Quote: "Trials that accrue the first enrollment beyond 2 months (n = 379, 49.6%) are significantly less likely to achieve the accrual performance than those trials that enroll patients under 2 months".
  5. 5.
    Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme · BMJ Open (Walters SJ et al.), via PubMed, 2017
    Abstract read October 2026; trials published 2004 to April 2016. Quote: "This review identified 151 individually RCTs from 787… moreAbstract read October 2026; trials published 2004 to April 2016. Quote: "This review identified 151 individually RCTs from 787 NIHR HTA reports. The final recruitment target sample size was achieved in 56% (85/151) of the RCTs".
  6. 6.
    Practical considerations for estimating clinical trial accrual periods: application to a multi-center effectiveness study · BMC Medical Research Methodology (Carter RE, Sonne SC, Brady KT), via PubMed, 2005
    Abstract read October 2026. Quote: "Projected recruitment rates are often over-estimated, and the time to recruit the target… moreAbstract read October 2026. Quote: "Projected recruitment rates are often over-estimated, and the time to recruit the target population (accrual period) is often under-estimated."
  7. 7.
    Effort required in eligibility screening for clinical trials · Journal of Oncology Practice (Penberthy LT et al.), via PubMed Central, 2012Read October 2026. Quote: "The average number of patients screened per enrolled patient ranged from three for observational studies to 13 for phase I studies."
  8. 8.
    45 CFR 164.512: Uses and disclosures for which an authorization or opportunity to agree or object is not required · eCFR, Office of the Federal Register, 2026
    Paragraph (i)(1)(ii), reviews preparatory to research. Quote: "No protected health information is to be removed from the covered… moreParagraph (i)(1)(ii), reviews preparatory to research. Quote: "No protected health information is to be removed from the covered entity by the researcher in the course of the review". Accessed September 2026; re-checked October 23, 2026.
  9. 9.
    Recruiting Study Subjects: Guidance for Institutional Review Boards and Clinical Investigators · U.S. Food and Drug Administration, 1998
    Issued January 1998. Quotes: "FDA considers direct advertising for study subjects to be the start of the informed consent and… moreIssued January 1998. Quotes: "FDA considers direct advertising for study subjects to be the start of the informed consent and subject selection process." "Advertisements should be reviewed and approved by the IRB as part of the package for initial review."
  10. 10.
  11. 11.
    Bond Health product information · Bond Health, 2026Capabilities, pricing and compliance status described by Bond Health, October 2026.

Related pages

Ready to get started?

Enroll patients faster.

See how Bond can accelerate enrollment for your clinical trials with a personalized demo.

Book a demo

Up to 3×

faster enrollment

90%+

matching accuracy

48 hrs

to EHR integration